High rates of liver disease progression and mortality observed in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH)
ILC 2019: New studies in Germany and France support the need for early detection and effective interventions among NAFLD/NASH patients 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE…
High cost of advanced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) revealed but screening high-risk patients may not be cost effective
ILC 2019: Italian study reveals high cost of advanced liver disease in NAFLD/NASH patients and missed opportunities to diagnose earlier, yet screening high-risk individuals for NAFLD may not be cost…
Obeticholic acid improves liver fibrosis and other histological features of nonalcoholic steatohepatitis (NASH)
ILC 2019: Interim analysis of the Phase 3 REGENERATE study suggests that obeticholic acid holds promise as a future treatment for NASH. 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
‘Real-world’ experience confirms effectiveness of sofosbuvir/velpatasvir/voxilaprevir in people with chronic hepatitis C (HCV) infection failing direct-acting antivirals (DAAs)
ILC 2019: ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs 10 April 2019,…